|
G Squared has closed its seventh flagship fund on $2.3bn, its largest vehicle to date, as the venture secondaries specialist looks to capitalise on the asset class moving from the sidelines to become a core feature of the industry.
The post G Squared lands record $2.3bn fund as venture secondaries become ‘core liquidity market' appeared first on AltAssets Private Equity News.
|
RELATED ARTICLES | | |
|
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
|
|
